SurveyMonkey Honors Standout Marketers as Winners of the Inaugural Curiosity Awards
SurveyMonkey, a global leader in online surveys and forms, today announced the winners of the inaugural SurveyMonkey Curiosity Awards. The awards program recognizes exceptional marketers at SurveyMonkey customer companies who are driving innovation and shaping what's next for marketing and their industries.
Winners of the 2024 Curiosity Awards:
Francisco Bram, VP of product marketing, brand and business development at Albertsons Companies
Susanna Canelon, director of social media and community engagement at University of the People
Alicia Cappelli, head of media partnerships at eBay
Irina Efremova, senior director of communications at Roblox
Abby Forsyth, brand manager of corporate and culture at MLSE, owner of the Toronto Maple Leafs (NHL), Toronto Raptors (NBA), and more
Brandon McKeown, communication specialist and media and creative content designer at City of Atlanta Department of Procurement
Elizabeth Montavon, director of athlete marketing and social media at Parity
Stella Sanchez, SVP of digital advertising and marketing operations at Teladoc Health
Bridget Sauer, head of customer marketing at Atlassian
Marques E. Zak, head of multicultural marketing at American Express
"One of my favorite things about SurveyMonkey is the diversity of our customer base, from local city entities to multinational corporations with offices around the world," said Eric Johnson, CEO at SurveyMonkey. "The winners of our Curiosity Awards exemplify this diversity and prove that innovation is driven by one common feature: curiosity. I'm proud to celebrate this year's winners and look forward to seeing them share their insights and expertise with the marketing community."
Several winners will also be featured at Curiosity Con, the annual virtual event from SurveyMonkey. Winners will be interviewed by Stuart Feil, Adweek's VP of branded content, and Katie Miserany, chief communications officer at SurveyMonkey. Register here: https://www.surveymonkey.com/mp/curiosity-con/.
About SurveyMonkey
SurveyMonkey is a global leader in online surveys and forms that empowers people with the insights they need to make decisions with speed and confidence. Our fast, intuitive feedback management platform connects millions of users worldwide with real-time AI-powered insights that drive meaningful decisions. We provide answers to more than 20 million questions every day so that people and organizations can attract new audiences, delight customers, create advocates, and extend their competitive advantage in the marketplace. Our vision is to raise the bar for human experiences by amplifying individual voices. Learn more at surveymonkey.com.
Amflow, the eMTB expert that builds e-bikes from heart to body, today marks its entry into the industry with the launch of the Amflow PL. Providing a significantly robust 850 W of peak power and weighing in at an industry leading level of ultra-light...
Daniels Manufacturing Corporation® (DMC®) is proud to announce the successful acquisition of MCD-Tools GmbH, a leading tool distribution and repair company based near Frankfurt, Germany. DMC's acquisition of MCD-Tools allows DMC to form DMC Europe...
NielsenIQ (NIQ) today announced the availability of NIQ Activate in the Microsoft Azure Marketplace, an online store providing applications and services for use on Azure. NIQ customers can now take advantage of the productive and trusted Azure cloud...
Owkin, the first end-to-end AI-biotech unicorn that provides best-in-class AI-driven precision drug discovery, development and diagnostics, has announced its expansion into the DACH region (Germany, Austria and Switzerland) following partnerships...
Manhattan Associates today announced that it has been named winner of the VIP Awards' Best Sustainability Initiative category for 2024. Selected from a competitive group of nominees, Manhattan Active® Supply Chain technology was chosen because of...
We are excited to share our latest development status.
We are pleased to announce that the enrollment of patients in the Phase III clinical trial of DFP-14323 in combination with Afatinib (20 mg/day) versus Afatinib (40 mg/day) alone in stage...